Clinical Trial Update: Rimonabant In Prediabetic Subjects To Delay Onset Of Type 2 Diabetes [Phase 3]

View source ↗

Summary

A Phase 3 trial of rimonabant in prediabetic individuals to delay onset of type 2 diabetes has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prediabetes
• Type 2 Diabetes Mellitus

Drugs mentioned

• Rimonabant (rimonabant)

Snippet

Sponsor: Sanofi | Conditions: Prediabetic State | Phase 3 | Status: TERMINATED